SCMS Seminar: An Academic Pharma Antimalarial Protease Inhibitor Collaboration: From Target Identification to Advance Leads Used to Decipher Intracellular Biology
SCMS Seminar
An Academic Pharma Antimalarial Protease Inhibitor Collaboration: From Target Identification to Advance Leads Used to Decipher Intracellular Biology
Dr. David Olsen
Infectious Disease R&D
Merck and Co
Abstract:
Malaria is a devastating disease that directly effects over half a million people each year with the most devastating and debilitating effects on young children. Antimalarial drug discovery, by and large, is focused on the identification of novel drugs to treat and prevent the disease due to the emergence and spread of Plasmodium strains resistant strains. In particular, artemisinin resistance which has now spread from SE Asia and is firmly established in Africa (as reported at ASTMH in Seattle Oct 2022). Merck, a large pharmaceutical company, paired up with an academic collaborator, Professor Alan Cowman and his colleagues to do some malaria parasite drug hunting. The resulting collaboration identified robust targeted aspartyl protease screening hits that required some creative biochemical target identification to nail down the exact mechanism of action. With some expert medicinal chemistry and detailed biological deciphering the team ended up with dual targeting molecules that are functionally active during the liver, blood and mosquito stage of the parasite’s replication cycle.
Intended Audience:
All are Welcome!
To request an interpreter, please visit myaccess.rit.edu
Event Snapshot
When and Where
Who
This is an RIT Only Event
Interpreter Requested?
No